Risks associated with fertility preservation for women with sickle cell anemia

Research output: Contribution to journalArticle

Abstract

Objective: To highlight the risk of complications among women with sickle cell anemia (SCA) receiving fertility preservation treatment (FPT) before hematopoietic stem cell transplant (HSCT). Design: Single-center case series. Setting: Academic fertility center. Patient(s): Women aged 15–32 years with SCA undergoing FPT before HSCT. Intervention(s): Retrospective, systematic review. Main Outcome Measure(s): FPT modality, SCA complications during FPT. Result(s): Over an 8-year period (2009–2017), seven women with SCA ages 15–32 years (mean 28.5 years) underwent FPT with embryo cryopreservation (n = 1), oocyte cryopreservation (n = 4), and ovarian tissue cryopreservation (n = 2). The five women subjects who underwent oocyte or embryo cryopreservation were treated with an antagonist controlled ovarian hyperstimulation protocol and individualized gonadotropin dosing. The trigger medications included leuprolide acetate (n = 2), and human chorionic gonadotropin (n = 3). Most patients (n = 5) received a disease-modifying therapy for SCA (hydroxyurea or chronic transfusions) before FPT. Three patients experienced periprocedural SCA complications that included life-threatening respiratory failure, painful crisis requiring interruption of a stimulation cycle, and severe postharvest painful crisis. Conclusion(s): Women with SCA may choose to undergo diverse FPT strategies before HSCT and are at risk for serious SCA-related complications. Evidence-based strategies to mitigate SCA-related morbidity and to optimize fertility preservation outcomes are needed.

Original languageEnglish (US)
Pages (from-to)720-731
Number of pages12
JournalFertility and Sterility
Volume110
Issue number4
DOIs
StatePublished - Sep 1 2018

Fingerprint

Fertility Preservation
Sickle Cell Anemia
Cryopreservation
Hematopoietic Stem Cells
Therapeutics
Transplants
Oocytes
Embryonic Structures
Leuprolide
Hydroxyurea
Chorionic Gonadotropin
Gonadotropins
Respiratory Insufficiency
Fertility
Outcome Assessment (Health Care)
Morbidity

Keywords

  • Bone marrow transplant
  • female infertility
  • fertility preservation treatment
  • sickle cell anemia
  • sickle cell disease

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Risks associated with fertility preservation for women with sickle cell anemia. / Pecker, Lydia; Maher, Jacqueline Y.; Law, Jennie Y.; Beach, Mary Catherine; Lanzkron, Sophie; Christianson, Mindy Sue.

In: Fertility and Sterility, Vol. 110, No. 4, 01.09.2018, p. 720-731.

Research output: Contribution to journalArticle

@article{8213990b032f418db3fdfe705513d946,
title = "Risks associated with fertility preservation for women with sickle cell anemia",
abstract = "Objective: To highlight the risk of complications among women with sickle cell anemia (SCA) receiving fertility preservation treatment (FPT) before hematopoietic stem cell transplant (HSCT). Design: Single-center case series. Setting: Academic fertility center. Patient(s): Women aged 15–32 years with SCA undergoing FPT before HSCT. Intervention(s): Retrospective, systematic review. Main Outcome Measure(s): FPT modality, SCA complications during FPT. Result(s): Over an 8-year period (2009–2017), seven women with SCA ages 15–32 years (mean 28.5 years) underwent FPT with embryo cryopreservation (n = 1), oocyte cryopreservation (n = 4), and ovarian tissue cryopreservation (n = 2). The five women subjects who underwent oocyte or embryo cryopreservation were treated with an antagonist controlled ovarian hyperstimulation protocol and individualized gonadotropin dosing. The trigger medications included leuprolide acetate (n = 2), and human chorionic gonadotropin (n = 3). Most patients (n = 5) received a disease-modifying therapy for SCA (hydroxyurea or chronic transfusions) before FPT. Three patients experienced periprocedural SCA complications that included life-threatening respiratory failure, painful crisis requiring interruption of a stimulation cycle, and severe postharvest painful crisis. Conclusion(s): Women with SCA may choose to undergo diverse FPT strategies before HSCT and are at risk for serious SCA-related complications. Evidence-based strategies to mitigate SCA-related morbidity and to optimize fertility preservation outcomes are needed.",
keywords = "Bone marrow transplant, female infertility, fertility preservation treatment, sickle cell anemia, sickle cell disease",
author = "Lydia Pecker and Maher, {Jacqueline Y.} and Law, {Jennie Y.} and Beach, {Mary Catherine} and Sophie Lanzkron and Christianson, {Mindy Sue}",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.fertnstert.2018.05.016",
language = "English (US)",
volume = "110",
pages = "720--731",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Risks associated with fertility preservation for women with sickle cell anemia

AU - Pecker, Lydia

AU - Maher, Jacqueline Y.

AU - Law, Jennie Y.

AU - Beach, Mary Catherine

AU - Lanzkron, Sophie

AU - Christianson, Mindy Sue

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Objective: To highlight the risk of complications among women with sickle cell anemia (SCA) receiving fertility preservation treatment (FPT) before hematopoietic stem cell transplant (HSCT). Design: Single-center case series. Setting: Academic fertility center. Patient(s): Women aged 15–32 years with SCA undergoing FPT before HSCT. Intervention(s): Retrospective, systematic review. Main Outcome Measure(s): FPT modality, SCA complications during FPT. Result(s): Over an 8-year period (2009–2017), seven women with SCA ages 15–32 years (mean 28.5 years) underwent FPT with embryo cryopreservation (n = 1), oocyte cryopreservation (n = 4), and ovarian tissue cryopreservation (n = 2). The five women subjects who underwent oocyte or embryo cryopreservation were treated with an antagonist controlled ovarian hyperstimulation protocol and individualized gonadotropin dosing. The trigger medications included leuprolide acetate (n = 2), and human chorionic gonadotropin (n = 3). Most patients (n = 5) received a disease-modifying therapy for SCA (hydroxyurea or chronic transfusions) before FPT. Three patients experienced periprocedural SCA complications that included life-threatening respiratory failure, painful crisis requiring interruption of a stimulation cycle, and severe postharvest painful crisis. Conclusion(s): Women with SCA may choose to undergo diverse FPT strategies before HSCT and are at risk for serious SCA-related complications. Evidence-based strategies to mitigate SCA-related morbidity and to optimize fertility preservation outcomes are needed.

AB - Objective: To highlight the risk of complications among women with sickle cell anemia (SCA) receiving fertility preservation treatment (FPT) before hematopoietic stem cell transplant (HSCT). Design: Single-center case series. Setting: Academic fertility center. Patient(s): Women aged 15–32 years with SCA undergoing FPT before HSCT. Intervention(s): Retrospective, systematic review. Main Outcome Measure(s): FPT modality, SCA complications during FPT. Result(s): Over an 8-year period (2009–2017), seven women with SCA ages 15–32 years (mean 28.5 years) underwent FPT with embryo cryopreservation (n = 1), oocyte cryopreservation (n = 4), and ovarian tissue cryopreservation (n = 2). The five women subjects who underwent oocyte or embryo cryopreservation were treated with an antagonist controlled ovarian hyperstimulation protocol and individualized gonadotropin dosing. The trigger medications included leuprolide acetate (n = 2), and human chorionic gonadotropin (n = 3). Most patients (n = 5) received a disease-modifying therapy for SCA (hydroxyurea or chronic transfusions) before FPT. Three patients experienced periprocedural SCA complications that included life-threatening respiratory failure, painful crisis requiring interruption of a stimulation cycle, and severe postharvest painful crisis. Conclusion(s): Women with SCA may choose to undergo diverse FPT strategies before HSCT and are at risk for serious SCA-related complications. Evidence-based strategies to mitigate SCA-related morbidity and to optimize fertility preservation outcomes are needed.

KW - Bone marrow transplant

KW - female infertility

KW - fertility preservation treatment

KW - sickle cell anemia

KW - sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=85052920429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052920429&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2018.05.016

DO - 10.1016/j.fertnstert.2018.05.016

M3 - Article

C2 - 30196969

AN - SCOPUS:85052920429

VL - 110

SP - 720

EP - 731

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 4

ER -